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Review
Emerging Trends for Radioimmunotherapy in Solid Tumors
Maneesh Jain,1 Suprit Gupta,1 Sukhwinder Kaur,1 Moorthy P. Ponnusamy,1 and Surinder K. Batra1,2
Abstract
Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic
modality for solid tumors. Poor tumor uptake and undesirable pharmacokinetics, however, have precluded the
administration of radioimmunoconjugates at therapeutically relevant doses thereby limiting the clinical utility of
RIT. In solid tumors, efficacy of RIT is further compromised by heterogeneities in blood flow, tumor stroma,
expression of target antigens and radioresistance. As a result significant efforts have been invested toward
developing strategies to overcome these impediments. Further, there is an emerging interest in exploiting short-
range, high energy a-particle emitting radionuclides for the eradication of minimal residual and micrometastatic
disease. As a result several modalities for localized therapy and models of minimal disease have been developed
for preclinical evaluation. This review provides a brief update on the recent efforts toward improving the
efficacy of RIT for solid tumors, and development of RIT strategies for minimal disease associated with solid
tumors. Further, some of promising approaches to improve tumor targeting, which showed promise in the past,
but have now been ignored are also discussed.
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Introduction
Radioimmunotherapy (RIT), despite its limited success insolid tumors, remains an attractive concept due to its
ability to potentially target both overt and occult lesions in an
antigen-specific manner. Poor tumor accretion (that reduces
efficacy), unfavorable pharmacokinetics (that cause dose-
limiting myelotoxicity) of antibody-based radiopharmaceuti-
cals, and radioresistance are the major impediments that
limit the efficacy of RIT. Thus, it is not surprising that much
of preclinical research has been centered on improving the
pharmacokinetics of radioimmunoconjugates, overcoming the
physiological barriers that result in limited delivery, searching
for ideal chemistries and radionuclide combinations for en-
hancing the therapeutic efficacy. Efforts have also been directed
toward developing combined modality therapies by including
cytotoxic and radiation-response modulating agents in con-
junction with RIT to enhance therapeutic response.
We have previously reviewed the utility of antibody engi-
neering to improve thepharmacokinetics andbiodistributionof
radiolabeled antibodies in solid tumors.1 Recently, we also re-
viewed various impediments that limit the delivery of radio-
immunoconjugates anddiscussed theexperimental approaches
investigated to modulate these barriers.2 Several articles have
reviewedvariousotheraspectsof solid tumorRIT, including the
roleof radiobiology in tumorcellkilling, clinical experiencewith
RIT, pretargeting strategies, targeted therapies, optimization of
delivery, and the use of various radionuclides for RIT.3–13
Development of efficient labeling methodologies has
fueled recent interest in exploiting short-range, high energy
a-particle emitting radionuclides for treating solid tumors by
RIT in a minimal residual disease setting. In addition to the
identification and use of new antigenic targets, RIT and
radioimmunoimaging strategies are also being developed
using monoclonal antibodies (MAbs) that are conventionally
approved as unlabeled therapeutic agents. Antiangiogenic
agents are being explored to improve the efficacy of both
cold and radiolabeled antibodies. On one hand, these new
developments provide hope for RIT-based approaches for
treating nonhematological malignancies. On the other hand,
these developments have introduced novel concepts, con-
cerns, and new models in the field of RIT. One of the
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emerging concepts is the possibility of targeting stem cells
with RIT. Some of the concerns include peritoneal toxicity of
a-emitter and variable response to antiangiogenic agents.
Recent efforts have been directed toward identification of ideal
radionuclides for intraperitoneal RIT, and development of
appropriate models for minimal residual disease after surgical
resection. In this review article we provide an update on
the recent developments for radiolabeled antibody-based
approaches for solid tumors. The review further discusses
some of the promising approaches tested in the past, to im-
prove tumor-to-tissue ratios (extracorporeal elimination) and
counter the problem of antigen heterogeneity (use of anti-
body cocktails) in tumors, but have now been forgotten or
ignored.
RIT and Minimal Residual Disease
In solid tumors, external beam radiation therapy (EBRT)
remains the method of choice for delivering a high radiation
dose to large tumors. There is an emerging consensus that the
primary role of RIT in solid tumors will be to treat micro-
metastatic disseminated disease or minimal residual disease
for preventing relapse. This has been reaffirmed with the
success of intraperitoneal RIT in the management of ovarian
cancer patients after debulking.14 Similarly, a phase I study
involving colorectal cancer patients with liver metastasis
demonstrated the usefulness of RIT over chemotherapy for
treating disseminated disease.15 Further, in a phase II trial, RIT
with 131I-labetuzumab (anti-CEA) after resection of liver me-
tastasis in colorectal cancer patients improved the overall sur-
vival, supporting the utility of RIT in an adjuvant setting.16,17
Intraperitoneal RIT: emerging trends
The peritoneal cavity is a preferable metastatic site for
several malignancies like ovarian, colorectal, pancreatic
cancers and mesotheliomas. Because of their disseminated
and microscopic nature, peritoneal metastases are difficult to
manage surgically and can benefit from RIT. Intraperitoneal
RIT can deliver high absorbed doses to locally confined
disease with minimal irradiation to radiosensitive organs
because of a slow and incomplete exchange with systemic
circulation.14 Hence, in comparison to systemic RIT, intra-
peritoneal RIT is more effective and less toxic. Several anti-
bodies conjugated with b-particle emitting radionuclides
were initially evaluated in clinical trials (reviewed in Mer-
edith et al.14). Several studies have been undertaken to iden-
tify the most suitable radionuclides (b-, a- or auger-emitters),
antibody formats [F(ab¢)2 IgG, IgM] and types (internalizing
vs. noninternalizing), and evaluating the toxicity of radionu-
clides on the peritoneal membrane.18–24 In the context of in-
traperitoneal RIT involving a-particle emitters, recent studies
have also explored their utility in several ways: multiple ad-
ministrations25 and the impact of using variable specific ac-
tivities26; compared the efficacy of intraperitoneal RIT with
pretargeted intraperitoneal RIT27; and investigated the impact
of antibody glycosylation on efficacy.28
Optimal radionuclides and antibody characteristics
for intraperitoneal RIT
The initial studies with intraperitoneal RIT have evaluated
b-particle emitting radionuclides, like 131I, 90Y and 177Lu due
to their clinical acceptability and availability.14,29–32 How-
ever, due to their higher linear energy transfer (LET) rates, a-
emitters are more potent in eradicating small lesions in the
peritoneal cavity. Further, due to their short half-life in
conjunction with the slow clearing kinetics of the peritoneal
cavity infusions, a-emitters are likely to have less nontarget
toxicity as compared to b-emitters. In fact, the first clinical
trial with an intraperitoneal administration of 211At-conju-
gated MX35 F(ab¢)2 (directed against sodium-dependent
phosphate transport protein 2b or NaPi2b) in ovarian cancer
patients demonstrated that the absorbed dose to the perito-
neum was >100 times more compared with red bone marrow
without any noticeable toxicity.21 In the intraperitoneal RIT
model of ovarian cancer, the 211At-conjugated MOv18 (anti-
folate MAb) exhibited greater therapeutic efficacy as compared
to 131I-MOv18.24 A direct comparison of 213Bi- and 177Lu-
labeled D9 MAb (specific for delta 9-1 mutant E-cadherin)
in intraperitoneal RIT indicated a similar therapeutic effi-
cacy against gastric cancer carcinomatosis. However, 177Lu-
labeled immunoconjugate was associated with adverse effects,
including lymphoblastic lymphoma, proliferative glomerulo-
nephritis, and hepatocarcinoma.18 The efficacy of RIT regi-
mens, including intraperitoneal RIT, is dependent on the
retention of radioimmunoconjugate at the target site. In a re-
cent study, Rauch et al. investigated the impact of the mo-
lecular size on the intraperitoneal retention of radiolabeled
antibodies.23 The D9 MAb described previously, was en-
gineered into Fab, IgG and IgM formats and the constructs
radiolabeled either with 213Bi or 111In were evaluated for re-
tention and biodistribution. Due to the differences in the half-
lives of the radioisotopes, the biodistribution of 213Bi-labeled
immunoconjugates was evaluated up to 180 minutes after
intraperitoneal administration, while 111In-labeled antibodies
were evaluated at 24 and 72 hours postadministration via
intraperitoneal and intravenous routes. Rapid accumulation of
213Bi-Fab was observed in the kidneys, while 213Bi-IgM and
213Bi-IgG exhibited the highest accumulations in the liver and
blood, respectively.23 Further, a higher accumulation of 111In-
IgM was observed in the liver and spleen 24 hours after i.v.
administration. Immunoscintigraphy indicated greater intra-
peritoneal retention of IgM compared to IgG after intraperi-
toneal administration. Peritoneal clearance is mediated by the
diffusion across peritoneal membrane, which provides greater
resistance to high molecular weight IgM as compared to
smaller IgG and Fab. However, radiolabeled IgM exhibited a
faster blood clearance rate than IgG that resulted in a rela-
tively shorter biological half-life of 111In-labeled IgM (24
hours) in comparison to IgG (165 hours). Thus, due to in-
creased peritoneal retention and rapid blood elimination, IgM
appear to be ideally suited for delivering a-emitters via intra-
peritoneal route.
Although most of the studies with intraperitoneal RIT
have involved b- and a-particle emitters, Pouget et al. have
demonstrated the utility of Auger electron-emitting radio-
nuclide 125I in conjunction with noninternalizing anti-
bodies.33 The energy of Auger electrons is about 20–50 keV
and can travel up to 2–500 nm in tissues. The cytotoxic effects
of a-particles and Auger electrons are attributed to their
ability to induce DNA damage. Thus, given their shorter
path length and low rates or linear energy transfer in com-
parison to a-emitters, the application of Auger electrons in
combination with noninternalizing antibodies may appear
640 JAIN ET AL.
counterintuitive. However, previous in vitro studies from the
group demonstrated that in comparison to internalizing
radioimmunoconjugates, noninternalizing 125I-labeled anti-
bodies exhibited more pronounced cell death suggesting the
sensitivity of the cell membrane to ionizing radiation.33
Subsequently, the therapeutic superiority of noninternalizing
125I-labeled antibodies in treating peritoneal carcinomatosis
was demonstrated in vivo using the vulvar squamous carci-
noma xenograft model.20 After intravenous administration,
the maximal tumor accretion of 125I-labeled noninternalizing
anti-CEA MAb 35A7 was significantly higher than radio-
iodinated internalizing anti-EGFR MAb m225. Further, 125I-
35A7 resulted in a higher dose deposition in the tumor than
125I-m225, produced greater reduction in tumor size and
significantly prolonged the median survival. On the other
hand, the dose deposition in the normal organs was com-
parable.20 Although the enhanced tumor accumulation can
be attributed to the resistance of noninternalized antibody to
dehalogenation, differences in antigen density and pharma-
cokinetic properties of the antibodies should also be carefully
examined before drawing definitive conclusions. Recently, a
‘‘brief intraperitoneal RIT’’ approach involving high dose
administration of noninternalizing 125I-35A7 was de-
scribed.19 In contrast to the previous study where 37MBq
125I-labeled MAbs were administered intravenously, in ‘‘brief
intraperitoneal RIT’’ 185MBq of radioimmunoconjugate was
administered intraperitoneally and the unbound antibody
was removed 1 hour postadministration by flushing the
peritoneal cavity with saline. SPECT imaging indicated that
after flushing the radioiodine signal was associated only
with the intraperitoneal tumors. The brief intraperitoneal RIT
resulted in a better tumor-to-blood ratio of 5 as compared to
intravenous RIT for which the tumor-to-blood ratio was 1.7.
The mean absorbed dose in tumor by brief intraperitoneal
RIT was comparable to intravenous RIT (11.6 Gy and 16.7
Gy, respectively); however, the latter resulted in significantly
higher absorbed doses in the normal tissues.
Impact of a-particles on the peritoneum
The localized delivery of radionuclides in intraperitoneal
RIT results in reduced toxicity to distant organs and bone
marrow. However, irradiation of peritoneal wall and visceral
organs can significantly increase toxicity. In clinical studies
involving EBRT and b-emitters, kidneys, liver and intestinal
crypts exhibit dose-limiting radiosensitivity.14,29–32,34–37 In
contrast, localized administration of a-emitters delivers a
high dose to the target site with minimal toxicity to the
surrounding tissues. Hence, radiosensitivity of the perito-
neum is the most likely anticipated concern in the context of
the intraperitoneal administration of a particles. Cederkrantz
et al. studied the effect of a radiation on normal mouse
peritoneum after intraperitoneal administration of 211At-
trastuzumab at varying doses ranging between 0–50 Gy.22
Peritoneum to plasma clearance was analyzed using 51Cr-
EDTA as a tracer, while inflammation was determined by
immunohistochemistry. Irradiated mice exhibited a slower
clearance than normal mice at a tolerable dose of 35 Gy,
indicating a dose-dependent reduction in the peritoneal ca-
pacity, whereas lethality was observed at 50 Gy. Im-
munohistochemical analysis for the plasminogen activator
inhibitor (PAI-1; a marker for peritoneal healing) and cal-
protectin (a marker of inflammation) revealed no differences
between various absorbed dose levels.22 These functional
and immunohistochemical findings suggested a limited risk
to the peritoneum by high dose localized administration of a-
emitters that are being extensively evaluated for intraperi-
toneal RIT.
RIT in animal models of minimal residual disease
and metastasis
While minimal residual disease accounts for relapse and
metastasis in most patients, there is a paucity of animal
models for evaluating therapeutic strategies like RIT in a
minimal disease or metastatic setting. Most preclinical
studies for RIT have employed subcutaneous xenograft
models that neither represent minimal disease nor metasta-
size to distant sites. However, several recent studies have
modeled minimal residual and metastatic disease in rat and
mouse models and evaluated the efficacy of RIT.38–45 Some
of the models of minimal disease and the RIT strategies
employed in these studies are schematically described in
Figure 1.
In a preclinical model and a phase I clinical trial, Behr et al.
provided one of the earliest evidences indicating that the
efficacy of RIT was comparable to chemotherapy in treating
small volume metastatic colorectal cancer with relatively
reduced side effects.15 For the preclinical studies, human
colon cancer cells (GW-39) were transplanted by intrasplenic
administration in athymic mice to induce multiple liver
metastases and treatment (chemotherapy or 131I-labeled
anti-CEA antibody) was initiated either on day 10 or 20
post-tumor implantation.15 The therapeutic efficacy of radio-
labeled antibodies in treating metastatic mammary cancer in
a HER-2/neu transgenic mouse model was evaluated re-
cently by Song et al.46,47 The transgenic mice expressing rat
HER2/neu under the control of MMTV promoter were
injected with rat HER2/neu-transfected mouse mammary
tumor cell line NT2.5 via either intracardiac or intravenous
routes. While the intracardiac inoculation resulted in meta-
static dissemination into the liver, spleen, and bone,46 the
intravenous injection of tumor cells caused lung metasta-
ses.47 In the disseminated metastatic model, RIT with 213Bi-
labeled anti-rat HER2/neu MAb was effective in controlling
early stage micrometastatic disease. Although the survival
improved from 28 days (control untreated animals) to 41
days after RIT, the increase in survival was not statistically
significant.46 In the lung metastasis model, the efficacy of
225Ac-, 213Bi-, and 90Y-labeled anti-rat HER2/neu was com-
pared.47 RIT was administered either 3 or 18 days after cell
implantation to model early and late stage disease, respec-
tively. 225Ac-labeled antibody was more effective in com-
parison to 213Bi- and 90Y-labeled antibody and significantly
improved the survival. In the early disease setting the 225Ac-
labeled antibody led to a complete eradication of disease in
67% of animals and with a median survival of 1 year.47 In
late stage disease, however, a-particle RIT was less effective
and 225Ac-labeled antibody resulted in a median survival
of 51 days.47 In an elegant study, Pfost et al. demonstrated
the utility of localized a-particle RIT for orthotopic blad-
der cancer.48 Transurethral resection is the standard of care
for patients with urothelial bladder cancer. However, the
procedure results in free floating cells, which frequently
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contribute to recurrence. To recreate this clinical scenario in a
mouse model, Pfost et al. performed electrocauterization of
the bladder wall via a catheter to mimic surgical resection.
This was followed by transcatheter instillation of luciferase-
labeled EJ28 human urothelial carcinoma cells, which were
allowed to settle for 2 hours.48 Intravesical RIT was per-
formed (via catheter) with 213Bi-labeled anti-EGFR MAb
(matuzumab) after 1 hour, 7 days, or 14 days postcell
instillation. RIT was highly effective in mice receiving radio-
labeled antibody either 1 hour or 7 days after cell in-
stillation as compared to mice receiving no treatment
(PBS), standard localized chemotherapy (intravesical mito-
mycin C) or RIT after 14 days.48 Again these findings dem-
onstrated the usefulness of a-particles in treating minimal
disease.
A series of models depicting various scenarios of minimal
disease or micrometastatic disease using syngeneic rat colon
carcinoma cells CC-531 was described in Wag/Rij rats. MAb
MG1 reactive against a 80 kDa antigen on the surface of CC-
531 cells was used for RIT. In a model with resected perito-
neal carcinomatosis, the 177Lu-MG1 antibody improved
survival after cytoreductive surgery as compared to chemo-
therapy.44,45 Koppe et al. also demonstrated the efficacy of
RIT in peritoneal carcinomatosis after cytoreductive sur-
gery.49 In these studies, rats were first injected intraperito-
neally with 2· 106 CC-531 cells and tumors were allowed to
grow for 14 days. Subsequently, the animals were allowed to
undergo cytoreductive surgery or exploratory laparotomy
and either left untreated or treated with intraperitoneal RIT
or chemotherapy. Increase in overall survival by 88 days and
eradication of tumor growth was observed with 74MBq of
177Lu-labeled MG1 after cytoreductive surgery.49 Improved
survival in rats with microscopic liver metastasis was also
demonstrated.39 CC-531 cells were injected in the portal vein
of Wag/Rij rats to induce liver metastasis followed by in-
travenous RIT with 177Lu-MG1 either at the day of inocula-
tion or 14 days postinoculation. A significant difference in
the survival was observed with RIT immediately after sur-
gery as compared to the control and 14 days after surgery,
indicating the relative usefulness of RIT for small micro-
scopic metastasis.39 Another model was tested to demon-
strate the utility of intravenous RIT as an adjuvant therapy
after the surgical removal of hepatic metastasis.40 Sub-
capsular inoculation of the tumor cells in the liver was per-
formed to initiate tumor formation. After 2 weeks, the liver
tumors were surgically resected and animals were subjected
to intravenous RIT with 177Lu-MG1 either within 3 hours or
7 days after resection. An improved overall survival was
observed with immediate administration of 177Lu-MG1
compared to the administration after 7 days, indicating the
efficacy of RIT as an adjuvant treatment modality.40 Utility of
RIT in an adjuvant setting to prevent local recurrence was
also demonstrated in another variation of a rat model of
minimal disease.38,41 The tumor cells were surgically im-
planted in the clamped colonic lumen and the tumor cells
were allowed to adhere to the walls for 30 seconds after
which, a 5mm section of the colon surrounding the needle
puncture was resected and the continuity was restored by
suturing.38,41 The animals were randomized and left un-
treated (PBS) or subjected to intraperitoneal RIT with 177Lu-
FIG. 1. Schematic representation of various models of minimal disease and metastases tested for evaluating solid tumor
RIT. These models have been developed either in mouse (colorectal cancer) or rats (bladder and breast cancer). A brief
description of methods for cell inoculation and subsequent procedures, if any, is provided in the boxes. RIT with b- or a-
particle emitters was administered by various routes as indicated and the details regarding the antibodies tested and cell lines
used is provided in the text. Most of these studies involved administration of RIT both immediately after cell inoculation or
surgical procedures and after a delay of 7–14 days to model both minimal disease and established tumors, respectively. CRC,
colorectal cancer; BC, breast cancer; MM, micrometastases; i.p., intraperitoneal; i.v., intravenous; RIT, radioimmunotherapy.
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MG1 either on the same day of surgery or 5 days post-
surgery.41 No tumor growth was found in the majority of the
animals administered with RIT on the day of surgery,
whereas animals receiving the RIT after 5 days developed
macroscopic tumors.41 The same model was also utilized to
compare the efficacy of RIT with chemotherapy in prevent-
ing local recurrence.38 While RIT and chemotherapy ex-
hibited comparable efficacy, RIT was associated with fewer
signs of acute toxicity as compared to chemotherapy.38
Targeting stem cells with radiolabeled antibodies
In various malignancies, cancer stem cells (CSCs) have
emerged as critical determinants of disease aggressiveness,
chemotherapy resistance and relapse.50–52 Hence, there is an
interest in developing therapeutic strategies targeting CSCs.
Radiolabeled antibodies conjugated to b-emitters can, in
theory, kill surrounding cells by a bystander ‘‘cross-fire’’ ef-
fect and this killing is independent of the expression of the
target antigen or the sensitivity of the cells to chemothera-
peutic drugs. Thus, RIT can be a potentially promising ap-
proach for eradicating CSCs. However, preclinical and
clinical studies have not determined the impact of RIT on
stem cells. Encouraged by the promising results in a clinical
trial with 188Re-labeled anti-Melanin MAb 6D2 (IgM) in pa-
tients with metastatic melanomas,53 Jandl et al. evaluated the
effect of 188Re-6D2 on the stem cells in a preclinical xenograft
model.54 As compared to untreated controls, the 188Re-6D2
treated animals had a fourfold decrease in tumor size. Re-
sected tumors were analyzed for melanoma stem cell
markers ABCB5 (marker of chemoresistant melanoma stem
cells) and JARID1B (marker for slow-cycling melanoma cells)
by immunohistochemistry and flow cytometry. Unlike chemo-
therapy which results in the enrichment of chemoresistant
stem cells, no change in the percentage of ABCB5 and JAR-
ID1B positive cells was observed in RIT-treated tumors as
compared to untreated tumors, indicating a similar rate of
killing of melanoma stem cells and bulk tumor cells. These
results suggested that chemoresistant and slow-cycling cells
are susceptible to b-emitter-based RIT.
While b-emitter-based radioimmunoconjugates can possi-
bly eradicate CSCs via a ‘‘cross-fire’’ effect, a more meaningful
approach will be to directly target CSCs in an antigen-specific
manner. CSCs are characterized by distinct surface markers.55
Several studies have established that CD133 and CD44 are the
universal surface markers for different cancers, including
brain, breast, ovarian, lung, prostate, pancreatic, hepatocellu-
lar, colon, and head and neck cancers.50–52,55
Two recent studies demonstrated the feasibility of target-
ing CD133 using antibodies in vivo. Tsurumi et al. utilized
two sets of isogenic CD133 positive (U251 glioblastoma cells
engineered to overexpress CD133 and HCT116 colon carci-
noma cells that have endogenous and uniform expression
of CD133) and negative cells (parental U251 and HCT116
p53 -/- derivative that have undetectable level of CD133)
to evaluate the in vivo targeting with anti-CD133 MAb
AC133.1.56 The study employed near infrared fluorescence
molecular tomography to quantitatively determine CD133-
specific tumor uptake of Cy 5.5-tagged antibody in xenograft
tumors. CD133 positive tumors could be reliably imaged
even after 7 days of systemic MAb administration. In the
titration experiments (mixing CD133 positive and negative
cells in different ratios), however, quantitative distinction
between CD133 positive and negative tumors was lost (sta-
tistically insignificant) if the proportion of CD133 positive
cells was less than 80%. This was attributed to the decreased
expression of CD133 in vivo as compared to the cells in cul-
ture and also due to some nonspecific uptake of labeled
antibody by macrophages via Fc receptors.56 In a similar
study, Jin et al. studied the biodistribution of 125I-labeled
anti-CD133 MAb in HCT116 xenograft tumor bearing mice
at a single time point postadministration (24 hours).57 As
compared to the control antibody, radioiodinated anti-
CD133 MAb ANC9C5 exhibited nearly a twofold higher
tumor uptake. However, a significantly higher uptake of the
specific antibody was observed in the stomach, while the
isotype control antibody exhibited significantly higher ac-
cumulation in the liver.57 Although the tumor uptake of the
specific antibody was modest, possibly due to the early time
point selected for biodistribution and lower expression of
CD133 in vivo, the study demonstrated in vivo targeting of
CD133 by radiolabeled MAb. CD44 is regarded as a CSC
marker in several malignancies including breast, prostate,
ovarian, colon, and pancreatic cancer. A recent study dem-
onstrated hypoxia-induced upregulation of CD44 in triple
negative breast cancer cells.58 An increase in CD44 expres-
sion in the hypoxic regions of MDA-MB-231 xenograft tu-
mors in vivo was determined by SPECT imaging after the
administration of 125I-labeled anti-CD44 MAb A3D8. The
hypoxic regions were imaged by optical imaging of tomato
RFP under the control of hypoxia-inducible promoter.58 Just
like studies with CD133, these studies utilized cells with an
inherently higher and uniform expression of CD44 (*80%
MDA-MB-231 express CD44). While the in vivo imaging
failed to address whether the increased uptake of the CD44
antibody was due to enhanced infiltration of CD44 positive
cancer stem cells in the hypoxic region or due to the upre-
gulation of CD44 in the cells in the hypoxic region, the fea-
sibility of in vivo targeting of CD44 by radiolabeled antibody
was established.
While none of these studies provided conclusive evidence
for successful targeting of rare CD133 or CD44 positive cancer
stem cells (as these studies utilized cells that uniformly ex-
pressed CD133 or CD44), the therapeutic potential of CD133
or CD44 targeting with radiolabeled antibodies should still be
evaluated in clinically relevant experimental models like the
models of minimal disease or in combination with chemo-
therapy. Rather than the absolute tumor uptake (by imaging
or biodistribution), stem cell-targeted RIT should evaluate the
eradication of CD133 or CD44 positive stem cells (as deter-
mined by prolonged survival and/or decreased recurrence) as
a viable endpoint to determine effectiveness.
Optimization of RIT: An Update
Antiangiogenic agents in the context of RIT
Poor uptake and heterogeneous intratumoral distribution
of therapeutic agents, including radiopharmaceuticals are the
direct manifestations of structural and functional abnormal-
ities of tumor vasculature. In contrast to normal vasculature,
tumor blood vessels are tortuous, dilated, hyperpermeable
and poorly interconnected, resulting in poor perfusion, in-
creased hypoxia, and elevated interstitial fluid pressure
(IFP). Encouraging outcomes in clinical studies with the
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combination of antiangiogenic agents with chemotherapy
were attributed to the so-called ‘‘vascular normalization’’
induced by antiangiogenic agents, presumably resulting in
transient improvement of blood flow, as well as delivery and
distribution of therapeutic agents. Several subsequent clinical
and preclinical studies have yielded contrasting results re-
garding the impact of antiangiogenic agents on drug deliv-
ery and there is an emerging consensus that the dosing and
scheduling of antiangiogenic agents should be carefully
planned and optimized in combination therapies. There are
multiple mechanisms by which antiangiogenic agents can
impact the outcome of RIT, both positively and negatively
(Fig. 2).
Several antiangiogenic agents have been demonstrated to
improve the efficacy of RIT. In a series of studies, Kinuya
et al. demonstrated the utility of exploiting the anti-
angiogenic properties of 2-methoxyestradiol (2-ME) and
thalidomide for improving the efficacy of RIT in experi-
mental models of colon cancer.59–62 Both 2-ME and thalido-
mide decreased the microvessel density in the tumors.
Antiangiogenic therapy improved the therapeutic efficacy of
131I-labeled anticolorectal cancer antibody A7 as determined
by a reduction in tumor growth in xenograft tumors and
improved survival in the hepatic metastasis model of colon
cancer induced by LS180.59–62 Similar enhancement in the
efficacy of anti-CEA directed RIT in combination with anti-
angiogenic therapy was observed in medullary thyroid car-
cinoma.63,64 Pretreatment with bevacizumab (anti-VEGF
antibody) before RIT with an 131I-labeled F(ab¢)2 fragment of
anti-CEA MAb F6 significantly prolonged the tumor volume
doubling time from 87 – 25 days to 127– 5 days without any
significant change in toxicity.63 A subsequent, more elaborate
study from the same group further demonstrated the bene-
fits of thalidomide and COBO11 (a VEGF inhibitor) in im-
proving the efficacy of CEA-directed RIT in both small and
large tumors.64 Enhancement in the efficacy of RIT was only
observed when the antiangiogenic agents were administered
before RIT, while post-RIT antiangiogenic therapy offered no
benefit. After thalidomide pretreatment, biodistribution
studies indicated increased tumor uptake of 125I-labeled anti-
body as compared to the control only at 24 hours, while
tumor uptake at 72 hours postadministration was similar.
This suggests that thalidomide possibly improved initial
tumor uptake because of enhanced tumor perfusion.64
Antiangiogenic therapy has also been evaluated in com-
bination with chemotherapy and unlabeled therapeutic an-
tibodies targeting EGFR family receptors in clinical studies
with both favorable and adverse outcomes. In HER2 positive
breast cancer patients, bevacizumab in combination with
trastuzumab and chemotherapy improved the outcome in
FIG. 2. Impact of antiangiogenic therapy on the efficacy of RIT. Antiangiogenic agents lead to destruction of tumor
vasculature resulting in decreased delivery of radiopharmaceuticals and increased hypoxia thereby decreasing the overall
efficacy of RIT. However, antiangiogenic agents also result in transient normalization of tumor vessels that can improve
delivery and decrease hypoxia that can improve the efficacy of RIT. Further, antiangiogenic agents can also result in the
entrapment of radiopharmaceuticals/chemotherapeutic agents that might have localized in the tumor before vessel de-
struction and this enhanced residence time can have a positive impact on therapeutic efficacy. Antiangiogenic agents can also
inhibit neovascularization of metastatic foci; thus, resulting in their growth arrest or dormancy. RIT can target these arrested/
dormant cancer cells in an antigen-specific manner and can potentially lead to complete eradication of metastatic disease in
combination with antiangiogenic therapy. RIT also induces antiangiogenic effects and can synergistically enhance the efficacy
of antiangiogenic agents. The complex interplay between antiangiogenic agents and RIT can result in distinct therapeutic
outcomes. Hence, it is absolutely critical to optimize the dosing and scheduling of antiangiogenic agents when used in
combination with RIT.
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Phase II trials.65–67 In contrast, in advanced colorectal can-
cers, the combination of chemotherapy and bevacizumab
with anti-EGFR antibodies (cetuximab and panitumumab)
failed to improve patient survival68–70 and exhibited adverse
effects to an extent of significantly reducing survival.70 To
determine the underlying cause of these diverse clinical
observations, two recent studies determined the impact of anti-
VEGF antibodies on the tumor uptake of radiolabeled anti-
bodies in experimental breast cancer models.71 Pastuskovas
et al. comprehensively studied the impact of anti-VEGF MAb
B20-4.1 (cross-reactive with both murine and human VEGF)
on the pharmacokinetics, biodistribution, and tumor pene-
tration of 111In- and 125I-labeled trastuzumab in a HER2 ex-
pressing KPL-4 xenograft model.71 Pretreatment with B20-4.1
resulted in decreased tumor uptake of tracer radiolabeled
trastuzumab in a dose dependent manner, while the uptake
in the nontarget tissues was unaffected. Autoradiographic
analysis indicated a more homogenous intratumoral distri-
bution of 111In-trastuzumab in untreated animals as com-
pared to B20-4.1 pretreated animals, where the tracer
antibody was restricted to the periphery. Anti-VEGF treat-
ment was found to significantly reduce the blood flow in the
tumor, while that in the normal tissue was unaffected.71
Similarly, Heskamp et al. demonstrated that bevacizumab re-
duced the uptake of 111In-labeled cetuximab and R1507 (anti-
EGFR and anti-IGF-1R antibodies, respectively) in SUM149
(breast cancer) xenograft tumors.72 Quantitative SPECT/CT
indicated that bevacizumab reduced tumor uptake of 111In-
cetuximab and 111In-R1507 by 40% and 35%, respectively.72
In the biodistribution studies, after bevacizumab pretreat-
ment, tumor targeting of radiolabeled cetuximab and R1507
was reduced by 44% and 29%, respectively, while the uptake
in normal tissues was unaltered. Further, this decrease was
associated with decreased microvessel density in the tumor,
while there was no change in the expression of the target
antigens (EGFR and IGF-1R).72
The utility of PDGFR inhibitor imatinib mesylate to im-
prove the efficacy of anti-TAG72 was previously demon-
strated using LS174T colorectal cancer xenografts.73 This
effect was accompanied by decreased tumor IFP that was
attributed to the effect of imatinib on stromal fibroblasts. In
contrast, in prostate cancer xenografts, the inhibition of
PDGFR-b signaling did not result in significant lowering of
tumor IFP but still appeared to improve the efficacy of RIT
possibly by modulating HIF1-a and reducing hypoxia.74
However, recent evidence suggests that imatinib can directly
impact tumor vasculature.75 Rajkumar et al. investigated the
impact of imatinib on the antibody uptake in LS174T and
SW1222 bearing xenograft models of colorectal cancer. The
LS174T and SW1222 xenografts exhibit distinct vascular ar-
rangements.75 While vasculature in LS174T tumors is sparse
and heterogeneous, SW1222 tumors have perfuse and homo-
genous vascular supply. Imatinib treatment resulted in a
more pronounced enhancement in tumor uptake and im-
proved intratumoral distribution of 125I-A5B7 antibody (anti-
CEA) only in LS174T tumors, while no significant changes
were observed in SW1222 tumors. However, reduced micro-
vessel and pericyte density was observed in both LS174T and
SW1222 xenografts.75 Confocal analysis demonstrated that
imatinib treatment reduced pericyte attachment to endothe-
lial cells in SW1222 tumors but not in LS174T tumors. The
impact of agents like PDGFR inhibitors on the uptake of
radiopharmaceuticals in a given tumor-type can be dictated
by various factors (architecture of tumor vasculature and
differential response of cells of tumor microenvironment)
and may involve distinct mechanisms. Therefore, caution
should be exercised in generalizing these criteria and ex-
trapolating the findings to other tumor-types and sub-types.
Extracorporeal Elimination: An Underexplored Avenue
to Reduce Myelotoxicity
Slow elimination of unbound radiolabeled immuno-
globulins is one of the primary causes of dose-limiting
myelotoxicity and poor tumor to normal tissue ratios of
antibody-based radiopharmaceuticals. It is also one of the
major impediments for RIT of solid tumors. Extracorporeal
elimination represents an attractive yet underexplored ave-
nue for the removal of unbound radioimmunoconjugates
for reducing their myelotoxicity and for administration of
higher doses. Extracorporeal elimination involves hema-
pheresis to remove the undesired substances and the purified
blood is returned back to the patient. In clinical settings,
extracorporeal elimination is employed for the management
of autoimmune diseases (removal of autoantibodies and
immune complexes), cases of poisoning, sepsis, and organ
transplantation.76–81
In a series of studies, Tennvall et al. have demonstrated
the utility of extracorporeal affinity adsorption using avidin
columns to deplete biotinylated radiolabeled antibodies from
circulation.82–92 In one of the earliest demonstrations of the
approach using athymic rats bearing human melanoma and
lung cancer xenografts, removal of biotinylated 125I-labeled
antimelanoma (MAb 96.5) and anticarcinoma (MAb L6)
antibodies improved the tumor to normal tissue ratios by a
factor of four or five.91 Subsequent studies using a syngeneic
model of colorectal cancer in rats with chimeric anti-Lewis
Y antibody BR96 demonstrated the benefits of immu-
noadsorption from the whole blood.85,88 A comparative
analysis of 111In- and 125I-labeled BR96 indicated that a more
pronounced improvement in tumor to normal tissue ratios
with 111In-BR96, following extracorporeal affinity adsorp-
tion; although the magnitude of reduction in the whole body
(39%–55%) and blood (79%–94%) was similar for both 111In-
BR96 and 125I-BR96.85 The group further demonstrated the
utility of extracorporeal affinity adsorption as a clearing step
in a two-step pretargeting approach involving biotinylated
BR96 and 111In-DOTA-streptavidin for improving the tumor
uptake and reducing nontarget tissue exposure.83 Improve-
ment in tumor-to-tissue ratios and reduced circulating
radioimmunoconjugates can potentially allow safer admin-
istration of higher doses. Direct experimental evidence for
the utility of extracorporeal affinity adsorption for increasing
the maximum tolerated dose (MTD) of the 90Y- and 177Lu-
labeled BR96 was recently reported.82 Antibodies were
radiolabeled with a trifunctional chelating agent 1033, which
contains DOTA and biotin. While the MTDs for 177Lu-1033-
BR96 and 90Y-1033-BR96 are close to 600 and 350MBq/kg,
respectively, extracorporeal affinity adsorption allowed
for administration of 1200MBq/kg 177Lu-1033-BR96 and
525MBq/kg of 90Y-1033-BR96 without any noticeable in-
crease in the toxicity.82
The feasibility and utility of extracorporeal elimination of
radioimmunoconjugates has also been demonstrated in
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human subjects. In lung and breast carcinoma patients, Lear
et al. tested the utility of extracorporeal immunoadsorption
of 111In-labeled murine antibody using a goat anti-mouse
antibody column. Imaging analysis indicated a 59% decrease
in the blood pool activity, while tumor activity was reduced
by only 10% thereby improving the tumor to blood ratios.93
In refractory B-cell lymphoma, extracorporeal elimination by
avidin affinity adsorption resulted in depletion of biotiny-
lated 90Y-rituximab from blood (96%), lungs (65%) whole
body (49%), liver (40%) and kidneys (40%).94 Importantly, no
adverse effects of avidin adsorption were observed on the
cellular or soluble components (complement activation,
bradykinin) of patient blood.95
Despite the evidence supporting the utility and feasibility,
extracorporeal elimination approaches have not gained
prominence in RIT. One of the primary reasons might be the
complexity of the approach itself. Because of the variability
in the pharmacokinetics of the antibodies and half-lives of
various radioisotopes, the scheduling and duration of ex-
tracorporeal elimination has to be carefully planned and
optimized. The optimized elimination window should allow
sufficient accretion of radioimmunoconjugates in the tumor
for effective therapy, while simultaneously limiting the ex-
posure to bone marrow to reduce myelotoxicity. Un-
fortunately, no suitable animal models are available for such
optimizations. Preclinical testing and optimization of cancer
therapies, including RIT has largely relied on mouse models.
However, the small blood volume of mice precludes the
possibility of accurately modeling hemaphoresis approaches.
Thus, it is no surprise that almost all the experimental evi-
dence for extracorporeal depletion was obtained using a rat
model. Yet the rat models for cancer are not well character-
ized and rodents, in general, due to their small size and
relatively radio-resistant bone marrow, are not ideally suited
to determine a dose-response relationship.82 Recently, the
utility of extracorporeal elimination for removing biotiny-
lated radiolabeled 111In- and 177Lu-labeled rituximab was
evaluated in a macaque model.96 The use of nonhuman
primates for evaluating and optimizing cancer therapies,
particularly RIT, is difficult due to the unavailability of well
characterized tumor models and cross-reactive antibodies; a
lack of information regarding target antigen expression; lo-
gistical challenges like cost, and requirement for shielded
animal housing.
Antigenic Heterogeneity and Antibody Cocktails
Tumors are characterized by physiological, genetic, spa-
tiotemporal and antigenic heterogeneities.97 Using a cocktail
of antibodies directed against multiple antigens expressed in
tumors can be a useful approach not only to improve the
tumor uptake but also to enhance tumor specificity. Several
preclinical and clinical studies have evaluated the utility of
antibody mixtures for improved tumor targeting.
In one of the earliest clinical studies involving antibody
cocktails, Chatal et al. evaluated the efficiency of 131I-labeled
MAbs 17-1A (anti-EpCAM) and 19-9 (anti-Sialyl Lea) in en-
hancing diagnostic sensitivity in a patient cohort predomi-
nantly comprised of GI malignancies.98 First, the antibodies
were evaluated individually (administered either as intact
MAb or F(ab¢)2 fragments) in 90 cancer patients. In the next
phase radioiodinated 19-9 was administered, either in com-
bination with 131I-17-1A or anti-CEA in 24 patients. Antibody
cocktail exhibited enhanced sensitivity (77%) as compared to
the individual antibodies (59% and 66% for 19-9 and 17-1,
respectively) in detecting the tumor sites.98 A subsequent
clinical study also demonstrated the utility combined tar-
geting of CEA and TAG-72 with 131I-labeled antibodies
(COL-1 and CC49, respectively) in colorectal cancer pa-
tients.99 Similarly, an additive or synergistic increase in
tumor cell reactivity in vitro and enhancement in tumor
contrast in vivo was observed with a mixture of F(ab¢)2 frag-
ments of MAbs GA 73-3 (reactive against 29, 30 and 37 kDa
protein antigens in carcinomas) and CO 29.11 (anti-Sialyl
Lea) in mice bearing colon carcinoma xenografts.100,101 Hay
et al. demonstrated the feasibility of targeting a receptor-
ligand pair by a radiolabeled antibody mixture.102 A tumor
xenograft model derived from transformed NIH3T3 cells
expressing c-met and its ligand hepatocyte growth factor
(HGF) either in a paracrine or autocrine setting, was utilized.
A mixture of five 125I-labeled antibodies (one anti-met + four
anti-HGF) was administered and evaluated for tumor tar-
geting by gamma camera imaging.102 Similarly, combined
targeting of EGFR and CD44 with 99mTc-labeled antibody
mixture resulted in increased tumor uptake and improved
tumor-to-normal tissue ratios in the lung cancer xenograft
model. The tumor to nontarget ratio for cocktail was found
to be 5.59 – 0.42 as compared to 2.78 – 0.20 and 2.28 – 0.16
for 99mTc-EGFR-mAb and 99mTc-CD44-mAb, respectively.103
Targeting dual molecules by a-radiation in vivo was recently
demonstrated by Milenic et al. using trastuzumab and hu-
manized CC49 (HuCC49DCH2) directed against HER2 and
TAG72, respectively.104 Intraperitoneal coadministration of
213Bi-labeled antibodies in athymic mice bearing dissemi-
nated intraperitoneal tumors (derived from LS174 colorectal
carcinoma cells) resulted in enhanced therapeutic efficacy
and improved survival by 4.3–4.7-fold compared to either
agent alone.104
In contrast to the antibodies directed against different an-
tigens, administration of the mixture of radiolabeled anti-
bodies directed against distinct epitopes of the same antigen
were found to be of limited value in preclinical and clini-
cal studies in melanomas.105,106 However, a mixture of three
scFVs (possibly targeting on different antigens) demon-
strated enhanced tumor localization compared to individual
scFvs in melanoma xenografts. Tumor uptake of the com-
bination was higher (%ID/g = 24.22%) compared to indi-
vidual scFvs (%ID/g = 2.854%, 2.263%, and 1.355%).107
Petronzelli et al. also demonstrated improved tumor target-
ing with a mixture of two antitenascin antibodies in a colon
carcinoma xenograft model.108 Coadministration of 125I-
labeled and biotinylated antitenascin antibodies ST2146
and ST2485 (directed against distinct epitopes adequately
spaced to rule out stearic hindrance) exhibited additive ac-
cumulation in HT29 xenografts as compared to the individ-
ual antibodies.108
Summary and Perspectives
Inadequate tumor delivery of radiolabeled antibodies and
their prolonged circulation have been the biggest roadblocks
for successful RIT of large solid tumors. However, promising
preclinical and clinical studies, particularly in the minimal
residual or micrometastatic disease settings, have raised
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hopes of clinical acceptability of RIT as an adjuvant therapy.
Recent research along these lines has been fueled by the ease of
availability of a-particle emitting radionuclides, possibility of
alternative routes of administration and development of ani-
mal models depicting minimal disease. Yet certain challenges
remain. To be effective, localized administration of high dose
of a-particle-based radiopharmaceuticals is desirable. How-
ever, there is still limited understanding regarding the non-
target toxicity of a-particles and studies need to be undertaken
to determine the radiosensitivity of candidate sites for local-
ized administration (peritoneum, bladder, pleural cavity, and
lungs). Further, while efficacy of RIT for minimal disease can
be determined by survival analysis, accurate determination of
tumor absorbed radiation dose remains a challenge. Similarly,
most animal models of minimal disease that have been uti-
lized for evaluating the efficacy of RIT have remained in the
confines of individual laboratories. While the feasibility of
targeting stem cell markers with radiolabeled antibodies has
been established, actual in vivo targeting of CSCs with specific
radiolabeled antibodies remains to be demonstrated. Future
studies should also test the effectiveness of RIT in controlling
or eradicating tumors seeded by CSCs.
Heterogeneity in tumor stroma and vasculature contribute
to heterogeneous distribution of radiopharmaceuticals in the
tumors. Efforts to modulate tumor stroma, particularly
tumor vasculature, for improving the delivery of radio-
pharmaceuticals and radiosensitivity of tumors have shown
promise. However, the interactions between RIT and stromal
modulators, like antiangiogenic agents, are complex and
mandate careful optimization of dosing and scheduling, use
of right models, and multiple cell lines before making
generalizations and predictions. In addition to antiangiogenic
agents, other avenues to remodel tumor stroma to make it
conducive to delivery of macromolecules need to be explored.
Heterogeneous distribution of radioimmunoconjugates has
also been attributed to the heterogeneity in target antigen
expression within the tumor. While the use of antibody
cocktails in preclinical and clinical studies has been demon-
strated to improve tumor targeting, most RIT research still
involves use of single antigen-antibody pair. With the advent
of personalized medicine and advances in sequencing tech-
nologies, a more rapid and robust genetic and molecular
characterization of tumors has become a reality. Such analysis
can more accurately predict the antigenic make-up of the tu-
mors and can facilitate in the formulating a tumor-type, and
patient-specific cocktail of radiopharmaceuticals.
Approaches to improve the pharmacokinetics of antibody-
based radiopharmaceuticals can significantly improve ad-
ministration of higher doses. While approaches like antibody
engineering and pretargeting have been explored extensively
to improve pharmacokinetics, approaches which are more
practical clinically, like extracorporeal elimination, have re-
ceived limited attention. One of the primary reasons could be
the lack of suitable animal models. While extracorporeal
elimination is more practical in humans and large animals, it
is challenging to model such an approach in mice due to their
small blood volumes. Preclinical RIT predominantly relies on
subcutaneous xenograft tumors grown in immunocompro-
mised athymic or severe combined immunodeficiency
(SCID) mice. Subcutaneous tumors do not recapitulate the
complexities of orthotopic tumors growing in the host organ.
The lack of intact immune system precludes the evaluation of
radiotoxicity on the immune system. The use of immuno-
compromised animals also eliminates the possibility of de-
termining the contribution of the immune system on the
therapeutic effects of radiopharmaceuticals. In the last de-
cade, various genetically engineered mouse models
(GEMMs) have been developed for various cancers. In con-
trast to xenograft models, the autochthonous tumors that
develop in GEMMs, more closely recapitulate the patho-
physiology of human cancers. Despite this promise, GEMMs
have not been utilized to evaluate RIT. One of the major
impediments for the use of GEMMs is their high cost. While
the cost of animals has increased alarmingly, the cost
GEMMs increases with the extent of engineering involved.
Ready-to-use GEMMs are difficult to obtain in appropriate
genetic background, while the maintenance of breeding
colonies of GEMMs is cost and labor intensive and often
requires specialized expertise in genetic engineering, breed-
ing and genotyping. Further, it is challenging to synchronize
tumor development and size in GEMMs that can potentially
hinder meaningful execution of RIT since the usability of
radiopharmaceuticals is dictated by the half-life of the ra-
dioisotopes. Another reason for the limited use of GEMMs in
RIT could be the predominance of antibodies reactive with
human tumor antigens and the available antibodies may not
always cross-react with mouse antigens. Further, the status
of widely studied RIT target antigens like CEA, TAG-72 and
PSMA in the GEMM tumors remains poorly characterized.
Yet some transgenic mouse models for human tumor asso-
ciated antigens like MUC1 and HER2/neu have been de-
veloped. These models would be the ideal starting points to
evaluate the efficacy of RIT in autochthonous tumors.
In conclusion, although there are several impediments in the
development of radiolabeled antibody-based therapeutic
strategies for solid tumors, recent publications have identified
several avenues to overcome the limitations of RIT. The greater
understanding of the factors that limit the delivery and efficacy,
availability of technologies for tailoring antibodies and devel-
opment of pertinent animal models will surely guide the in-
creased clinical acceptability of RIT for solid tumors.
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